Hutchmed China Limited Adr (HCM)

개요 뉴스 가격 이력 옵션 체인 토론 예측

Relative Volume:

Hutchmed China Limited Adr Stock (HCM) Company Profile

Hutchmed China Limited Adr

Healthcare (1175)

최신 SEC 제출 서류

HCM's Discussions on Twitter

HCM을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
HCM Hutchmed China Limited Adr	15.47	2.88B	630.20M	37.73M	-17.44M	0.20
RGC Regencell Bioscience Holdings Ltd	15.63	303.95B	0	-5.87M	-767.30K	-0.45
ZTS Zoetis Inc	159.17	74.39B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.35	48.97B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	15.43	47.39B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	16.72	20.17B	16.54B	-1.64B	749.00M	-1.45

Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-05-13	다운그레이드	HSBC Securities	Buy → Hold
2023-11-24	업그레이드	Deutsche Bank	Hold → Buy
2022-05-04	다운그레이드	Deutsche Bank	Buy → Hold
2021-09-22	다운그레이드	Goldman	Buy → Neutral
2021-08-03	개시	Jefferies	Buy
2020-10-02	개시	Deutsche Bank	Buy
2020-03-13	개시	Cantor Fitzgerald	Overweight
2020-02-20	개시	Goldman	Buy
2019-11-19	개시	CLSA	Buy
2019-10-23	재확인	BofA/Merrill	Buy
2019-07-05	개시	Macquarie	Outperform

Hutchmed China Limited Adr 주식(HCM)의 최신 뉴스

Hutchmed China Limited Adr (HCM) 재무 분석

Hutchmed China Limited Adr (HCM)

Hutchmed China Limited Adr Stock (HCM) Company Profile

HCM을(를) 다른 주식과 비교

Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades

Hutchmed China Limited Adr 주식(HCM)의 최신 뉴스

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Bought by Bank of America Corp DE - Defense World

Public Employees Retirement System of Ohio Has $39,000 Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Two Sigma Investments LP Sells 12,471 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High? - sharewise

Market news - investments.halifax.co.uk

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma - The Manila Times

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma - Yahoo Finance

HUTCHMED and Innovent Jointly Announce NDA Acceptance in - GlobeNewswire

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma - GlobeNewswire Inc.

Northern Trust Corp Sells 10,700 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Millennium Management LLC Sells 100,366 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

D. E. Shaw & Co. Inc. Trims Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

BNP Paribas Financial Markets Trims Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Jane Street Group LLC Grows Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Barclays PLC Purchases 2,255 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times

UPDATEInternational companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Globe and Mail

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Manila Times

International companies to host live webcasts at Deutsche - GlobeNewswire

HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com

Marshall Wace LLP Acquires New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - The AM Reporter

CN Reportedly Directs Pharmas, Hospitals to Study Feasibility of Substituting US Imported Products - AASTOCKS.com

RCSHutchmed China LtdHUTCHMEDData to be Presented at AACR 2025 - TradingView

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - Yahoo Finance

HUTCHMEDOncology portfolio growth expected to continue - Research Tree

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World

Richard Li Invited to Attend China Development Forum, Pictured with Li Qiang and Others - AASTOCKS.com

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewswire

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewswire

Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - The Manila Times

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 - GlobeNewswire

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 - AsiaOne

HUTCHMED (HCM) Upgraded to Buy: Here's Why - Yahoo Finance

Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade - Yahoo Finance

CN NMPA Guides Pharmas, Research Institutes to Enlarge R&D of Innovative Drugs, High-Quality Generic Drugs - AASTOCKS.com

ABC Arbitrage SA Buys New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat

Sea Limited Sponsored ADR (SE) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance

Crossmark Global Holdings Inc. Increases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

CN Healthcare Fund Breaks even w/ Slim Surplus in 2024 - AASTOCKS.com

HUTCHMED Announces NMPA Full Approval for - GlobeNewswire

UBS Trims HUTCHMED (00013.HK)TP to $38.7 w/ Rating Buy - AASTOCKS.com

Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week - Yahoo Finance

HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com

Hutchmed announces progress, hits milestone with lung cancer treatment - ShareCast

Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification - OncLive

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - The Manila Times

HUTCHMED Announces NDA Acceptance in China with Priority - GlobeNewswire

Hutchmed China Limited Adr (HCM) 재무 분석

매출

순이익

현금흐름

주당 순 이익

HCM과 유사한 종목